Neoadjuvant chemotherapy   

Masuda et al. NEJM 2017 If so, how do you sequence it with adjuvant radiotherapy?

Would you prefer TCHP over TCH? Would you consider adding an anthracycline?

How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?

Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?

If so, what regimen? 

(For instance, TCx4 instead of ddAC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemother...